跳至主要内容
临床试验/NCT00425763
NCT00425763已完成4 期

Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya

Centers for Disease Control and Prevention1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2007年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
110
试验地点
1
主要终点
28 Day Adequate Clinical and Parasitological Response, Early Treatment Failure, Late Clinical Failure, Late Parasitological

研究概览

简要总结

We will be studying the clinical efficacy of amodiaquine-artesunate currently being studied in an intermittent preventive therapy in infants (IPTi)trial in the same area in order to correlate preventive efficacy seen in IPTi with efficacy for treatment of symptomatic malaria for each regimen.

详细描述

We propose to conduct an amodiaquine-artesunate efficacy trial at Bondo District Hospital in Kenya. The results will enable us to better interpret the results of the main IPTi trial. We will assess the efficacy of a three day course of amodiaquine plus three days of artesunate (AQ3/AS3) for the treatment of symptomatic, uncomplicated P. falciparum infections. Study subjects are febrile children, 6-59 months old, with laboratory-confirmed uncomplicated P. falciparum infections. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. Children will be followed closely for signs of drug failure or recrudescence, and any children failing therapy will be treated with Coartem or, if severe, with quinine. We will also perform drug resistance testing on parasite samples from children with treatment failure. The results of this efficacy trial will allow us to assist policymakers in deciding what drugs should be used for IPTi, should it be adopted into national policy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Months 至 59 Months(Child)
性别
All
接受健康志愿者

入选标准

  • age 6-59 months
  • axillary temperature ≥ 37.5º C, or history of fever in previous 24 hours
  • weight ≥ 5.0 kg
  • slide-confirmed infection with P. falciparum
  • parasitemia 2000-200,000 asexual forms per μl
  • ability and willingness to attend stipulated follow-up visits

排除标准

  • signs or symptoms of severe disease
  • weight-for-age ≤ 3rd percentile on Kenya growth charts
  • slide confirmed infection with any other Plasmodium spp., besides falciparum
  • severe anemia, defined as Hb < 7 g/dl
  • known hypersensitivity to any of the drugs being tested
  • enrolled in IPTi trial
  • known chronic disease

研究组 & 干预措施

AQAS

Experimental

干预措施: AQAS (Drug)

结局指标

主要结局

28 Day Adequate Clinical and Parasitological Response, Early Treatment Failure, Late Clinical Failure, Late Parasitological

次要结局

  • Side effects
  • Molecular markers of drug resistance

研究者

研究点 (1)

Loading locations...

相似试验